Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences Inc (ENVB) is a biotechnology innovator developing neuroplastogenic therapies for mental health disorders. This page serves as the definitive source for all company announcements, research milestones, and industry developments.
Access real-time updates on clinical trials, regulatory progress, and strategic partnerships. Investors will find curated press releases covering therapeutic advancements like EB-003's neuroplasticity mechanisms and EB-002's prodrug technology, alongside financial disclosures and executive insights.
Our news collection prioritizes accuracy and timeliness, offering:
• Clinical development updates
• Regulatory pathway announcements
• Peer-reviewed research highlights
• Strategic collaboration news
Bookmark this page for streamlined tracking of ENVB's progress in creating non-hallucinogenic psychiatric treatments. Verify information directly through primary sources via provided documentation links when available.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focusing on mental health and oncology treatments, announced that Dr. Joseph Tucker, CEO, will participate in two upcoming conferences: the A.G.P. Biotech & Specialty Pharma Conference on October 13, 2021, and the KCSA Psychedelics Investor Conference from October 13-14, 2021. Dr. Tucker will present live on October 13 at 11:30 a.m. ET. Interested parties can register for the events through provided links. Enveric is developing innovative treatments using psychedelic-derived molecules and synthetic cannabinoids.
Enveric Biosciences (NASDAQ: ENVB) has announced that its AI tool, PsyAI, has successfully identified potential psychedelic drug candidates from its database of 500 compounds. This technology enhances the drug discovery process for challenging mental health issues, including cancer-related distress and PTSD. Using machine-learning models, PsyAI predicts the drug potential and helps categorize compounds, which could streamline the development of viable drug candidates. Enveric aims to improve treatment options for patients suffering from debilitating conditions.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on mental health and oncology treatments, announced participation in two investor conferences. CEO Dr. Joseph Tucker will take part in the Maxim's Advances in Mental Health Virtual Conference on September 22 at 10:00 a.m. ET, discussing 'Next Gen Psychedelics: Novel Chemical Entities'. He will also present at the Benzinga's Healthcare Small Cap Virtual Conference on September 30 at 3:40 p.m. ET. Enveric aims to address mental health issues using psychedelic-derived molecules and synthetic cannabinoids.
Enveric Biosciences (NASDAQ: ENVB) has successfully closed its acquisition of MagicMed Industries, a biotechnology firm focused on developing psychedelic molecules for mental health treatments. This all-stock transaction gives Enveric access to a novel library of psychedelic derivatives, enhancing its drug development pipeline targeting conditions like cancer-related distress, PTSD, and anxiety. Enveric issued approximately 9.95 million shares to MagicMed shareholders, with existing Enveric shareholders retaining 68.3% ownership. Dr. Joseph Tucker, former CEO of MagicMed, will lead Enveric as its new CEO.
Enveric Biosciences (NASDAQ: ENVB) announced that Dr. Joseph Tucker, CEO of MagicMed Industries, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 and the Virtual Gravitas Health Reimagined Investor Day on September 16. Enveric is developing cannabinoid medicines aimed at improving the quality of life for cancer patients, with an annual meeting scheduled for September 14. The upcoming presentations underline the company's commitment to innovation in oncology therapy through the acquisition of MagicMed.
Enveric Biosciences (NASDAQ: ENVB) issued an open letter to shareholders on August 18, 2021, highlighting its upcoming stockholder meeting on September 14, 2021, and the expected acquisition of MagicMed Industries. The company holds a strong balance sheet with approximately $20 million in cash and no debt, allowing for future mergers and acquisitions. Enveric is expanding its R&D capabilities and plans to invest in mental health initiatives. Additionally, a new patent was granted for cancer treatment using CBD, and regulatory approvals for the MagicMed transaction have been secured, pending shareholder votes.
Enveric Biosciences (NASDAQ: ENVB) announced approval from the Israeli Ministry of Health to commence the Phase 1/2 study of its lead asset, EV101, aimed at treating recurrent glioblastoma (GBM) using synthetic cannabidiol (CBD) combined with clomiphene and temozolomide. The study will assess the safety, maximum tolerated doses, and initial efficacy on patients at the Davidoff Institute of Oncology. The first patient is targeted for enrollment in Q4 2021. The goal is to improve treatment outcomes and quality of life for GBM patients, addressing a high unmet medical need.
Enveric Biosciences (NASDAQ: ENVB) announced participation in various investor and industry conferences in June 2021, following its May 24 announcement of acquiring MagicMed Industries. Key speakers include David Johnson and Dr. Joseph Tucker, who will present at conferences such as the Benzinga Capital Conference, LD Micro Invitational XI, and H. C. Wainwright Conference. These events aim to showcase their innovative approaches to developing naturally occurring medicines to enhance the quality of life for cancer patients.
Enveric Biosciences (NASDAQ: ENVB) announced its definitive agreement to acquire MagicMed Industries, enhancing its portfolio with psychedelic-derived molecules for cancer and CNS therapies. The all-stock transaction involves approximately 9.9 million shares issued to MagicMed shareholders and is expected to close in the second half of 2021. Dr. Joseph Tucker, MagicMed’s CEO, will become Enveric’s CEO post-acquisition. Enveric aims to address cancer-related PTSD, leveraging MagicMed’s research capabilities and novel drug candidates. Additionally, Enveric will receive approximately $4 million CAD from MagicMed's treasury.
Enveric Biosciences (NASDAQ: ENVB) reported its financial results for Q1 2021, highlighting a net loss of $3.25 million and a significant increase in operating expenses to $6.76 million, up from $0.84 million in Q1 2020. The company raised $24.88 million through financing activities, primarily from the sale of common stock. With approximately $23 million in cash as of March 31, 2021, Enveric is positioned to initiate two critical Phase I/II trials for Glioblastoma Multiforme and Radiation Dermatitis later this year. Management changes include the appointment of a new CFO and enhancements to the Scientific Advisory Board.
